Evidence map›Paper›PMID 28465529›Full record

ArticleLeukemia2017

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.

M K Hasan, J Yu, L Chen, Bing Cui, G F Widhopf Ii, L Rassenti, Z Shen, S P Briggs, T J Kipps

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Role of the Ror family receptors in Wnt5a signaling.In vitro cellular & developmental biology. Animal · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

M K HasanMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
J YuMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
L ChenMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Bing CuiMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
G F Widhopf IiMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
L RassentiMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Z ShenSection of Cell and Developmental Biology, University of California San Diego, La Jolla, CA, USA.
S P BriggsSection of Cell and Developmental Biology, University of California San Diego, La Jolla, CA, USA.
T J KippsMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
University of California, San Diego · US

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
NCI NIH HHS P01 CA081534
6 · The paper itself

Abstract

ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a conserved, oncoembryonic surface antigen expressed in chronic lymphocytic leukemia (CLL). We found that ROR1 associates with hematopoietic-lineage-cell-specific protein 1 (HS1) in freshly isolated CLL cells or in CLL cells cultured with exogenous Wnt5a. Wnt5a also induced HS1 tyrosine phosphorylation, recruitment of ARHGEF1, activation of RhoA and enhanced chemokine-directed migration; such effects could be inhibited by cirmtuzumab, a humanized anti-ROR1 mAb. We generated truncated forms of ROR1 and found its extracellular cysteine-rich domain or kringle domain was necessary for Wnt5a-induced HS1 phosphorylation. Moreover, the cytoplamic, and more specifically the proline-rich domain (PRD), of ROR1 was required for it to associate with HS1 and allow for F-actin polymerization in response to Wnt5a. Accordingly, we introduced single amino acid substitutions of proline (P) to alanine (A) in the ROR1 PRD at positions 784, 808, 826, 841 or 850 in potential SH3-binding motifs. In contrast to wild-type ROR1, or other ROR1

Indexed as

Adaptor Proteins, Signal TransducingAmino Acid SequenceBlood ProteinsCell MovementChemokinesHumansLeukemia, Lymphocytic, Chronic, B-CellMultiprotein ComplexesPhosphorylationProtein BindingProtein Interaction Domains and MotifsReceptor Tyrosine Kinase-like Orphan ReceptorsrhoA GTP-Binding ProteinRho Guanine Nucleotide Exchange FactorsTumor Cells, CulturedWnt-5a ProteinAdaptor Proteins, Signal TransducingARHGEF1 protein, humanBlood ProteinsChemokinesHCLS1 protein, humanMultiprotein ComplexesReceptor Tyrosine Kinase-like Orphan ReceptorsrhoA GTP-Binding ProteinRho Guanine Nucleotide Exchange FactorsROR1 protein, humanWnt-5a ProteinWNT5A protein, human

Identifiers

PMID28465529
PMCPMC5670028
OpenAlexW2611877356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.